Michael Esposito, MD
Urology · Maywood, NJNPI 1154390458
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $24,710 of the $28,018 with a category attached, or 88.2%. Procept Biorobotics Corporation accounts for 91.5% of it on its own, with 28 other manufacturers making up the rest. Among urology clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 105 payments — averaging $266.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Procept Biorobotics Corporation$26K
- Johnson & Johnson$283
- Intuitive Surgical$272
- Astellas Pharma US Inc$229
- Vertos Medical, Inc.$227
- Boston Scientific$204
- plus $1K from 23 others
Across 3 payments — averaging $16,667 each. An ownership or investment interest held by the physician or an immediate family member.
- New Wave Endo-surgical Corp.$50K
What the payments were for
- Consulting fees$24,71088%
- Travel & lodging$1991%
- Food & beverage$2,99811%
- Education$1110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Procept Biorobotics Corporation | 27 | $25,642 |
| Johnson & Johnson(2 entities) | 3 | $283 |
| Intuitive Surgical | 4 | $272 |
| Astellas Pharma US Inc | 10 | $229 |
| Vertos Medical, Inc. | 5 | $227 |
| Boston Scientific | 5 | $204 |
| Kerecis Limited | 4 | $155 |
| Bayer | 8 | $147 |
| Urogen Pharma, Inc. | 4 | $100 |
| Coloplast | 1 | $89 |
| Myovant Sciences Inc. | 4 | $65 |
| Biotissue Holdings Inc. | 1 | $64 |
| Tolmar, Inc. | 4 | $61 |
| AbbVie | 4 | $58 |
| Pfizer | 4 | $54 |
| Davol Inc. | 1 | $51 |
| Abbott | 1 | $49 |
| Calyxo, Inc. | 1 | $45 |
| Dendreon Pharmaceuticals LLC | 3 | $43 |
| Mimedx Group, Inc. | 1 | $25 |
| Metuchen Pharmaceuticals | 2 | $23 |
| Seapearl East, Inc | 1 | $22 |
| Olympus America Inc. | 1 | $19 |
| Axonics, Inc. | 1 | $19 |
| Endo USA, Inc. | 1 | $19 |
| Urovant Sciences Inc | 1 | $15 |
| Endo Pharmaceuticals Inc. | 1 | $15 |
| Tolmar Pharmaceuticals, Inc. | 1 | $15 |
| Amniox Medical, Inc. | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AQUABEAM SYSTEM$13,725
- AquaBeam Robotic System$11,794
- STRATAFIX$271
- SURGICEL NU-KNIT$154
- Echelon Flex$154
- GENERAL KIDNEY STONE DISEASE$120
- VISTASEAL$117
How this compares
$28,018 in reported general payments places this provider in the 90th percentile of 401 urology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiaflexCollagenase Clostridium Hist. | 15 | $197,780 |
| NubeqaDarolutamide | 13 | $177,359 |
| MyrbetriqMirabegron | 59 | $51,798 |
| GemtesaVibegron | 48 | $51,051 |
| Tamsulosin Hcl | 643 | $14,335 |
| Finasteride | 658 | $12,634 |
| Methenamine Hippurate | 153 | $9,920 |
| Silodosin | 66 | $6,686 |
| ToviazFesoterodine Fumarate | 13 | $6,162 |
| Tadalafil | 64 | $5,237 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 144 | $4,101 |
| Dutasteride | 67 | $3,612 |
| Bethanechol Chloride | 46 | $3,496 |
| Solifenacin Succinate | 67 | $2,936 |
| Potassium Citrate ErPotassium Citrate | 15 | $1,362 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Endo Pharmaceuticals Inc.Xiaflex | $15 | $197,78015 claims |
| BayerNubeqa | $147 | $177,35913 claims |
| Astellas Pharma US IncMyrbetriq | $229 | $51,79859 claims |
| PfizerToviaz | $54 | $6,16213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 401 urology providers in New Jersey.
Other urology in Maywood
- Mutahar AhmedMaywood$414K
- Michael StifelmanHackensack$1.4M
- Gordon BrownCherry Hill$1.3M
- Thomas MuellerLinwood$1.1M
- David SussmanLinwood$802K
- Michael IngberDenville$530K
- Ravi MunverHackensack$529K
- Grannum SantBridgewater$487K
- Kevin GioiaRumson$143K
- Robert SimonCliffside Park$108K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.